Sensus Healthcare, Inc.: Form 10-Q for the period ended Jun 30, 2021
Filed with the SEC on Aug 13, 2021 and accepted by EDGAR at Aug 13, 2021, 10:09 ET.
Management's discussion and analysis
As filed, 14,939 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
You should read the following discussion and analysis in conjunction with the information set forth within the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our Management’s Discussion and Analysis of Financial Condition and Results of Operations in the 2020 Annual Report.
Overview
Sensus Healthcare, Inc. (together, with its subsidiary, unless the context otherwise indicates, “Sensus” or the “Company”) is a medical device company committed to providing highly effective, non-invasive and cost-effective treatments for both oncological and non-oncological skin conditions. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on over a decade of dedicated research and development and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world. With the introduction of Sculptura™, the Company has branched out into cancer treatment that goes far beyond skin and may provide a revolutionary treatment option for patients around the world.
Impact of COVID-19
The outbreak of COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has adversely impacted the U.S. and global economies, as well as the Company’s employees, operations, and customer demand. The Company has been able to continue to operate and service its customers throughout the pandemic. However, the pandemic significantly impacted the Company’s sales throughout 2020 and into 2021, as social distancing forced physicians to temporarily close their practices and could further impact the Company’s operations and the operations of the Company’s customers, suppliers and vendors as a result of ongoing quarantines, facility closures, and travel and logistics restrictions. The extent to which the COVID-19 pandemic impacts the Company’s business, results of operations and financial condition will depend on future developments. The Company cannot reasonably estimate the impact at this time. Sensus continues to service customers amid uncertainty and disruption linked to COVID-19 and is actively managing its business to respond to the impact.
Segment Information
The Company manages its business globally within one reportable segment, which is consistent with how our management reviews
Results of Operations
| For the Three Months Ended June 30, 2021 | 2020 | For the Six Months Ended June 30, 2021 | 2020 | |
|---|---|---|---|---|
| Revenues | $5,422 | $1,183 | $8,492 | $2,862 |
| Cost of sales | 2,077 | 543 | 3,561 | 1,514 |
| Gross profit | 3,345 | 640 | 4,931 | 1,348 |
| Operating expenses: | ||||
| Selling and marketing | 1,254 | 1,162 | 2,322 | 2,953 |
| General and administrative | 1,445 | 904 | 2,417 | 2,233 |
| Research and development | 925 | 1,148 | 1,586 | 2,373 |
| Total operating expenses | 3,624 | 3,214 | 6,325 | 7,559 |
| Income (loss) from operations | (279) | (2,574) | (1,394) | (6,211) |
| Other income (expense) | ||||
| Interest income | - | 14 | 1 | 65 |
| Interest expense | - | (14) | (1) | (14) |
| Other income (expense), net | - | - | - | 50 |
| Net income (loss) | $(279) | $(2,574) | $(1,394) | $(6,161) |
Three months ended June 30, 2021 compared to the three months ended June 30, 2020
Revenues were $5.4 million for the three months ended June 30, 2021 compared to $1.2 million for the three months ended June 30, 2020, an increase of $4.2 million or 358%. The increase was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the three months ended June 30, 2020.
Cost of sales was $2.1 million for the three months ended June 30, 2021 compared to $0.5 million for the three months ended June 30, 2020, an increase of $1.6 million, or 283%. The increase in cost of sales was commensurate with the increase in sales in the three months ended June 30, 2021.
Gross profit was $3.3 million for the three months ended June 30, 2021 compared to $0.6 million for the three months ended June 30, 2020, an increase of $2.7 million, or 423%. Our overall gross profit percentage was 61.7% in the three months ended June 30, 2021 compared to 54.1% in the corresponding period in 2020. The increase in gross profit was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the three months ended June 30, 2020.
Selling and marketing expense was $1.3 million for the three months ended June 30, 2021 compared to $1.2 million for the three months ended June 30, 2020, an increase of $0.1 million, or 8%. The net increase in selling and marketing expense was primarily due to higher commission expense offset by a reduction in headcount.
General and administrative expense was $1.4 million for the three months ended June 30, 2021 compared to $0.9 million for the three months ended June 30, 2020, an increase of $0.5 million, or 60%. The net increase in general and administrative expense was primarily due to higher legal and professional fees, public company expenses and insurance premium costs.
Research and development expense was $0.9 million for the three months ended June 30, 2021 compared to $1.1 million for the three months ended June 30, 2020, a decrease of $0.2 million, or 19%. The decrease in research and development spending reflected lower spending as the SculpturaTM project entered production phase during 2020.
Six months ended June 30, 2021 compared to the six months ended June 30, 2020
Revenues were $8.5 million for the six months ended June 30, 2021 compared to $2.9 million for the six months ended June 30, 2020, an increase of $5.6 million or 197%. The increase was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the six months of 2020.
Cost of sales was $3.6 million for the six months ended June 30, 2021 compared to $1.5 million for the six months ended June 30, 2020, an increase of $2.1 million, or 135%. The increase in cost of sales was commensurate with the increase in sales in the six months ended June 30, 2021.
Gross profit was $4.9 million for the six months ended June 30, 2021 compared to $1.3 million for the six months ended June 30, 2020, an increase of $3.6 million, or 266%. Our overall gross profit percentage was 58.1% in the six months ended June 30, 2021 compared to 47.1% in the corresponding period in 2020. The increase in gross profit was primarily driven by the higher number of units sold in 2021, service revenue on installed units and the impact of COVID-19 in the six months ended June 30, 2020.
Selling and marketing expense was $2.3 million for the six months ended June 30, 2021 compared to $3.0 million for the six months ended June 30, 2020, a decrease of $0.7 million, or 21%. The decrease was primarily attributable to a decrease in tradeshows expense due to cancellations related to COVID-19, reduced marketing activities including travel and salary and benefit expenses due to reduced headcount.
Research and development expense was $1.6 million for the six months ended June 30, 2021 compared to $2.4 million for the six months ended June 30, 2020, a decrease of $0.8 million, or 33%. The decrease in research and development spending reflected lower spending as the SculpturaTM project entered production phase during 2020.
Financial Condition
The following discussion summarizes the significant changes in assets and liabilities. Please see the condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020 contained in Part I, Item 1 of this filing.
Assets
Cash and cash equivalents at June 30, 2021 increased $297 thousand, see Cash Flows for details on the change in cash and cash equivalents during the six months ended June 30, 2021.
Accounts receivable at June 30, 2021 increased $803 thousand from December 31, 2020, primarily due to receivables for increase in sales of units in the six months ended June 30, 2021.
Inventories at June 30, 2021 decreased $1.3 million from December 31, 2020, primarily due to increased shipments of units sold in the six months ended June 30, 2021.
Prepaid and other current assets at June 30, 2021 decreased $585 thousand primarily due to the amortization of prepaid expenses.
Liabilities
There were no borrowings under the revolving line of credit at June 30, 2021 or December 31, 2020.
Liquidity and Capital Resources
The Company’s liquidity position and capital requirements may be impacted by a number of factors, including the following:
- ability to generate and increase revenue;
- fluctuations in gross margins, operating expenses and net results; and
- fluctuations in working capital.
The Company’s primary short-term capital needs, which are subject to change, include expenditures related to:
- expansion of sales and marketing activities; and
- expansion of research and development activities.
Sensus’ management regularly evaluates cash requirements for current operations, commitments, capital requirements and business development transactions, and may seek to raise additional funds for these purposes in the future.
Cash flows
The following table provides a summary of cash flows for the periods indicated:
(in thousands)
| Net cash provided by (used in): | For the Six Months Ended June 30, 2021 | 2020 |
|---|---|---|
| Operating activities | $241 | $2,567 |
| Investing activities | 170 | 6,781 |
| Financing activities | (1134) | 967 |
| Total | $297 | $10,315 |
Net cash provided in operating activities was $0.2 million for the six months ended June 30, 2021, consisting of a net loss of $1.4 million and an increase in net operating assets of $0.9 million and non-cash charges of $0.7 million. Cash flows used in operating activities primarily include the receipt of revenues offset by the payment of operating expenses incurred in the normal course of business, including year-end incentive compensation accrued for in the prior year. Net cash provided by operating activities was $2.6 million for the six months ended June 30, 2020, consisting of a net loss of $6.2 million partially offset by a decrease in net operating assets of $8.0 million and by non-cash charges of $0.8 million.
Net cash provided by investing activities for the six months ended June 30, 2021 reflected $0.2 million of proceeds from the sale of property and equipment, partially offset by purchases of property and equipment. Net cash provided by investing activities was $6.8 million, mostly due to matured investments of $6.5 million during the six months ended June 30, 2020.
Net cash used in financing activities for the six months ended June 30, 2021 primarily reflected $0.1 million of loan repayments and withholding taxes on stock compensation. Net cash provided by financing activities was $1.0 million during the six months ended June 30, 2020 mostly from a loan under the Small Business Administration Paycheck Protection Program of $1.0 million.
Indebtedness
Please see Note 4, Debt, to the financial statements.
Contractual Obligations and Commitments
Please see Note 7, Commitments and Contingencies, to the financial statements.
Off-Balance Sheet Arrangements
The Company did not have during the periods presented, and does not currently have, any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. Actual results could differ significantly from those estimates. For a summary of these and additional accounting policies see Note 1, Organization and Summary of Significant Accounting Policies, to the financial statements. In addition, see Critical Accounting Policies in Management’s Discussion and Analysis of Financial Condition and Results of Operations and Note 1, Organization and Summary of Significant Accounting Policies, in the 2020 Annual Report for further information
JOBS Act
Sensus is an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act. As such, the Company can take advantage of exemptions from various reporting requirements that are applicable to other public companies but not to “emerging growth companies,” including, but not limited to:
- being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
- not being required to comply with the auditor attestation requirements in the assessment of the Company’s internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;
- reduced disclosure obligations regarding executive compensation in the Company’s periodic reports and proxy statements; and
- exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Sensus is expected to remain an emerging growth company until December 31, 2021, following which it is expected to continue to be a “smaller reporting company,” which will enable it to continue to take advantage of many of these exemptions, as discussed below. Investors may find Sensus’ common stock less attractive if the Company chooses to rely on these exemptions. If some investors find Sensus’ common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for the Company’s common stock and the price of its common stock may be more volatile.
In addition, an emerging growth company can delay its adoption of certain accounting standards until those standards would otherwise apply to private companies. However, the Company has chosen to “opt out” of such extended transition period, and as a result, plans to comply with any new or revised accounting standards on the relevant dates on which non-emerging growth companies must adopt such standards. Section 107 of the JOBS Act provides that the decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.
Controls and procedures
As filed, 917 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Control and Procedures
As of June 30, 2021, the end of the period covered by this Form 10-Q, our management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer each concluded that, as of June 30, 2021, the end of the period covered by this Form 10-Q, we maintained effective disclosure controls and procedures.
Changes in Internal Control over Financial Reporting
There have been no significant changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 561 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A. “Risk Factors” in our 2020 Annual Report, as updated in our subsequent quarterly reports. The risks described in our 2020 Annual Report and our subsequent quarterly reports are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or operating results.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-04-01 to 2021-06-30 | $5.4m | us-gaap:Revenues |
| Revenue | 6 months2021-01-01 to 2021-06-30 | $8.5m | us-gaap:Revenues |
| Cost of revenue | 3 months2021-04-01 to 2021-06-30 | $2.1m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2021-01-01 to 2021-06-30 | $3.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2021-04-01 to 2021-06-30 | $3.3m | us-gaap:GrossProfit |
| Gross profit | 6 months2021-01-01 to 2021-06-30 | $4.9m | us-gaap:GrossProfit |
| Research and development | 3 months2021-04-01 to 2021-06-30 | $925.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2021-01-01 to 2021-06-30 | $1.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2021-04-01 to 2021-06-30 | −$279.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2021-01-01 to 2021-06-30 | −$1.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 6 months2021-01-01 to 2021-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-04-01 to 2021-06-30 | −$279.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2021-01-01 to 2021-06-30 | −$1.4m | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2021-01-01 to 2021-06-30 | $241.0k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2021-01-01 to 2021-06-30 | $87.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2021-06-30 | $15.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-06-30 | $24.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-06-30 | $26.4m | us-gaap:Assets |
| Current liabilities | At period end2021-06-30 | $5.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-06-30 | $6.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2021-06-30 | $20.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-21-042324. Last ingested by Listed: Nov 14, 2026, 13:10 ET. Listed shows no prices and gives no investment advice.